CoChat

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia

Open access
Packer, Leisl M., Rana, Sareena, Hayward, Robert, O'Hare, Thomas, Eide, Christopher A., Rebocho, Ana, Heidorn, Sonja, Zabriskie, Matthew S., Niculescu-Duvaz, Ion, Druker, Brian J., Springer, Caroline, Marais, Richard · 2011 · Cancer Cell
Cited by 124

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Summary We show that imatinib, nilotinib and dasatinib possess weak off-target activity against RAF and therefore drive paradoxical activation of BRAF and CRAF in a RAS-dependent manner. Critically, since RAS is activated by BCR-ABL, in drug-resistant chronic myeloid leukemia (CML) cells RAS activity persists in the presence of these drugs, driving paradoxical activation of BRAF, CRAF, MEK and ERK, and leading to an unexpected dependency on the pathway. Consequently, nilotinib synergizes with MEK inhibitors to kill drug-resistant CML cells and block tumor growth in mice. Thus, we show that imatinib, nilotinib and dasatinib drive paradoxical RAF/MEK/ERK pathway activation and have uncovered a synthetic lethal interaction that can be used to kill drug-resistant CML cell in vitro and in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2011.11.004

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 124

Metadata

Authors
Packer, L. M., Rana, S., Hayward, R., O'Hare, T., Eide, C. A., Rebocho, A., Heidorn, S., Zabriskie, M. S., Niculescu-Duvaz, I., Druker, B. J., Springer, C., & Marais, R.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2011-12
Volume
20
Issue
6
Pages
715-727
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2083607012
Cited by
124
References
1
FWCI
6.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. https://app.cochat.ai/papers/10.1016/j.ccr.2011.11.004
The paper
Packer, L. M., Rana, S., Hayward, R., O'Hare, T., Eide, C. A., Rebocho, A., Heidorn, S., Zabriskie, M. S., Niculescu-Duvaz, I., Druker, B. J., Springer, C., & Marais, R. (2011). Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia. Cancer Cell. https://doi.org/10.1016/j.ccr.2011.11.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.